AAV PN
Alternative Names: AAV-PNLatest Information Update: 10 Oct 2024
Price :
$50 *
At a glance
- Originator Latus Bio
- Class Antidementias; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Alzheimer's disease; Angelman syndrome; Frontotemporal dementia; Rett syndrome
Most Recent Events
- 25 Sep 2024 Early research in Alzheimer's disease in USA (Intraventricular) (Latus Bio pipeline, September 2024)
- 25 Sep 2024 Early research in Angelman syndrome in USA (Intraventricular) (Latus Bio pipeline, September 2024)
- 25 Sep 2024 Early research in Frontotemporal dementia in USA (Intraventricular) (Latus Bio pipeline, September 2024)